Oxford, United Kingdom
coding.bio is a biotechnology startup based in the United Kingdom, founded in 2020. The company's slogan, "building best-in-class cell therapies through automation & computation," reflects its core focus on accelerating Cell Therapy using AI and synthetic biology driven discovery. Their recent achievement includes securing a Seed Round investment on 05 September 2023, with 2048 Ventures as the lead investor.
coding.bio's innovative approach leverages advanced technologies to revolutionize the development of cell therapies, positioning them at the forefront of the industry. With their emphasis on automation and computation, the company is well-positioned to disrupt the traditional biotechnology landscape and drive significant advancements in cell therapy. The recent investment from 2048 Ventures further validates their potential and underscores their appeal to investors.
As the biotechnology sector continues to experience substantial growth and demand for advanced cell therapies rises, coding.bio appears to be a promising player with a compelling vision and strategic execution. Their focus on AI and synthetic biology sets them apart, offering a distinct competitive advantage in the pursuit of best-in-class cell therapies. This recent investment marks a significant milestone for coding.bio, signaling a vote of confidence from 2048 Ventures and providing the necessary fuel for their continued innovation and expansion within the biotechnology space.
